Payment overview · 2025
General Payments
$294.81
18 reported records · 9 companies
Healthcare provider profile · identity verified
Christopher Todd Marazon, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · GALLIPOLIS, OH · NPI 1700803699
Verified facts
What the public records show
CMS Open Payments records show Christopher Todd Marazon, D.O. received $294.81 in general payments during 2025 across 18 reported records.
Amgen Inc. accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.85 | 17.6% | 3 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.34 | 17.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.84 | 16.2% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $46.72 | 15.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.76 | 9.8% | 2 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $22.43 | 7.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.89 | 5.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.85 | 5.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.13 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $294.81 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.85 | 3 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $51.34 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $46.72 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.28 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.72 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.72 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
91 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 533 | 160 |
| Levothyroxine Sodium | Levothyroxine Sodium | 382 | 112 |
| Lisinopril | Lisinopril | 336 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 291 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 277 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 259 | 77 |
| Losartan Potassium | Losartan Potassium | 239 | 67 |
| Gabapentin | Gabapentin | 237 | 56 |
| Eliquis | Apixaban | 217 | 34 |
| Omeprazole | Omeprazole | 199 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 189 | 54 |
| Furosemide | Furosemide | 167 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 127 | 32 |
| Potassium Chloride | Potassium Chloride | 127 | 39 |
| Ezetimibe | Ezetimibe | 113 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 43 |
| Allopurinol | Allopurinol | 96 | 24 |
| Sertraline Hcl | Sertraline Hcl | 95 | 30 |
| Famotidine | Famotidine | 94 | 36 |
| Simvastatin | Simvastatin | 92 | 33 |
| Synthroid | Levothyroxine Sodium | 91 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 27 |
| Trazodone Hcl | Trazodone Hcl | 89 | 22 |
| Carvedilol | Carvedilol | 88 | 28 |
| Montelukast Sodium | Montelukast Sodium | 87 | 27 |
| Metformin Hcl | Metformin Hcl | 86 | 28 |
| Metformin Hcl Er | Metformin Hcl | 85 | 26 |
| Meloxicam | Meloxicam | 83 | 27 |
| Glimepiride | Glimepiride | 79 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 69 | 16 |
| Spironolactone | Spironolactone | 68 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | 11 |
| Alprazolam | Alprazolam | 62 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 29 |
| Farxiga | Dapagliflozin Propanediol | 58 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 58 | 14 |
| Finasteride | Finasteride | 54 | 15 |
| Jardiance | Empagliflozin | 52 | 16 |
| Ozempic | Semaglutide | 50 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 14 |
| Benazepril Hcl | Benazepril Hcl | 48 | 16 |
| Buspirone Hcl | Buspirone Hcl | 48 | 17 |
| Donepezil Hcl | Donepezil Hcl | 45 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | suppressed |
| Atenolol | Atenolol | 43 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 21 |
| Amoxicillin | Amoxicillin | 40 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 14 |
| Meclizine Hcl | Meclizine Hcl | 38 | 14 |
| Warfarin Sodium | Warfarin Sodium | 38 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 26 |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Cephalexin | Cephalexin | 35 | 27 |
| Lorazepam | Lorazepam | 35 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Nystatin | Nystatin | 23 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 17 |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 13 |
| Lovastatin | Lovastatin | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 14 |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $294.81 · 18 records | Amgen Inc. | AIRSUPRA, Kerecis GraftGuide, Kerecis SurgiClose, LEQVIO, MAVYRET, NUZYRA, OTEZLA, QULIPTA, REPATHA, The Cologuard Plus Collection Kit, UBRELVY, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error